Agilent acquires Lab901

Edinburgh-based electrophoresis equipment and consumables company, Lab901, has been acquired by Agilent Technologies for an undisclosed amount.

"With the addition of Lab901's outstanding technology and talented team, Agilent can now address customer needs across the entire span of electrophoresis life science applications — from semi-automated to 96-well-plate compatible workflows," said Patrick Kaltenbach, vice president of Agilent's Liquid Phase Separations business. "Alongside our existing BioAnalyzer platform and the Agilent G7100 Electrophoresis System, the Lab901 ScreenTape system provides a very versatile, automated and scalable throughput gel electrophoresis solution for a wide range of applications."

Lab901 develops and markets benchtop electrophoresis instruments, plastic-based consumables and associated reagents, used in pharma, bio-pharma R&D and quality control for DNA, RNA and protein analysis.

"We have always recognized the strong synergy between our two companies," said Joel Fearnley, Lab901's former CEO, who will join Agilent Technologies along with the rest of his employees. "We look forward to offering our global customers an unrivalled portfolio of advanced products to address their electrophoresis needs."

For more information about the companies go to www.agilent.com and www.lab901.net